Sun Pharmaceutical Industries Limited
NSE: SUNPHARMA | Information Technology
Market Fundamentals
Stock Intelligence & News
Indian Industry Celebrates $20.5 Billion Investment In US; Announce $1.1 Billion Projects
Indian pharmaceutical companies announced plans to invest more than $19.1 billion in the United States, anchored by Sun Pharmaceutical's planned $11.75 billion acquisition of New Jersey-based Organon & Co.
Read Full Analysis →Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "SPARC Announces Sale of Priority Review Voucher for US $195 million". |SUBJECT: Press Release
Read Full Analysis →Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages say
Sun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in women's health. The deal diversifies Sun Pharma's portfolio into women's health and biosimilars, with analysts from Morgan Stanley and Motilal Oswal expressing bullish sentiment, while JM Financial remains cautious about long-term value creation.
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscape
Sun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The deal leverages Organon's strengths in women's health, biosimilars, and established brands, aiming for significant growth despite geopolitical concerns. Integration plans and manageable debt are key to the strategic move.
Read Full Analysis →Bullish on power, energy, and BFSI; cautious on IT amid weak earnings: Devarsh Vakil
HDFC Securities sees opportunity in India's recovering equity markets. The firm favors power and energy sectors, citing infrastructure growth. Financials, including banks and NBFCs, are also preferred. However, the IT sector faces an underweight stance due to uncertain earnings. Sun Pharma's growth strategy and Varun Beverages' expansion are noted positively.
Read Full Analysis →Sun Pharmaceutical Industries Limited
SUN PHARMACEUTICAL INDUSTRIES LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire) |SUBJECT: Acquisition (including agreement to acquire)-XBRL
Read Full Analysis →Sun Pharma Joins the Big Table With Organon Acquisition
Sun Pharma Joins the Big Table With Organon Acquisition
Read Full Analysis →Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal
Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal
Read Full Analysis →Sun Pharma Management Expects Organon Acquisition To Unlock Cost Synergies Worth $350 Million
Sun Pharmaceutical on Monday announced the acquisition of New York-listed Organon in an allcash transaction
Read Full Analysis →Organon Jumps 15% as Sun Pharma Agrees $11.8bn Buyout
Organon Jumps 15% as Sun Pharma Agrees $11.8bn Buyout
Read Full Analysis →Get instant alerts when SUNPHARMA breaks news
Join investors who track Sun Pharmaceutical Industries Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for SUNPHARMA?
SUNPHARMA is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Sun Pharmaceutical Industries Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding SUNPHARMA to your custom watchlist.